VSEE Stock Risk & Deep Value Analysis
Vsee Health Inc
Healthcare • Health Information Services
DVR Score
out of 10
What You Need to Know About VSEE Stock
We analyzed Vsee Health Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran VSEE through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
VSEE Risk Analysis & Red Flags
What Could Go Wrong
The company faces an imminent risk of NASDAQ delisting following a staff notice, which could force its shares to trade on OTC markets, drastically reducing liquidity and market visibility. This, coupled with historical severe financial distress and negative operating cash flow (estimated -$5.79M TTM), means VSEE could run out of capital within 12 months if new financing is not secured, leading to insolvency or further extreme dilution.
Risk Matrix
Overall
Aggressive
Financial
High
Market
High
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
NASDAQ delisting notice (material regulatory risk).
- ⚠
Severe financial distress: negative net income (-$57.7M TTM), negative operating cash flow (-$5.79M TTM), and negative book value (-$0.33 per share), as per previous analysis and likely ongoing.
- ⚠
Micro-cap status ($0.01B market cap) indicates extreme volatility and lack of institutional coverage.
- ⚠
Low transparency: Public filings (10-K, 10-Q) are referenced but actual financial content is not readily available in provided research, obscuring current financial health.
Upcoming Risk Events
- 📅
Confirmation of NASDAQ delisting (immediate-Q3 2026): Would likely lead to forced sale of shares or migration to OTC, severely limiting liquidity and price discovery.
- 📅
Inability to secure additional financing (Q2-Q4 2026): Without capital, operations are unsustainable, leading to potential bankruptcy or further dilution/down-round financing.
When to Reconsider
- 🚪
Exit if NASDAQ delisting is confirmed by the appeals committee, as this will severely impact liquidity and valuation.
- 🚪
Sell if the company fails to announce a significant capital raise (e.g., >$5M) by Q4 2026, indicating continued inability to fund operations.
- 🚪
Exit if new financial filings show accelerating cash burn or further deterioration in margins without corresponding revenue growth.
Unlock VSEE Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Vsee Health Inc (VSEE) Do?
Market Cap
$9.02M
Sector
Healthcare
Industry
Health Information Services
Employees
154
VSee Health, Inc. provides telehealth care solutions in the United States. The company offers iDoc Telehealth solutions that treat and coordinate care for acutely ill patients in the neurointensive care, cardiac intensive care, and intensive care units for stroke, spinal cord, brain trauma, and other neurological conditions. It also provides telehealth software building blocks, such as patient engagement, clinician staffing, remote physical exam and remote patient monitoring, and AI for telesitter and telenursing solutions; data connectors; and workflow templates. The company distributes its products through third-party resellers and affiliated hospitals, as well as sales executives. VSee Health, Inc. is headquartered in Newton, Massachusetts.
Visit Vsee Health Inc WebsiteInvestment Thesis
If VSEE successfully appeals the NASDAQ delisting notice and subsequently secures significant new financing (e.g., >$5M) by Q4 2026 to stabilize its operations and potentially pivot or gain traction with a specialized telehealth solution, then the stock could experience a highly speculative re-rating from its current distressed valuation. This is bullish only for investors willing to bet on an extreme turnaround from near-insolvency, as the market is pricing in delisting and potential failure.
Is VSEE Stock Undervalued?
Unlock the full AI analysis for VSEE
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
VSEE Price Targets & Strategy
12-Month Target
$0.05
Bull Case
$0.50
Bear Case
$0.00
Valuation Basis
Based on severe dilution and potential delisting. A speculative rebound to $0.50 would require an extreme turnaround, while $0.00 reflects delisting and total value destruction.
Entry Strategy
Only for extremely high-risk speculative capital, consider minimal entry below $0.10, acknowledging total loss is highly probable.
Exit Strategy
Take 100% profit if price reaches $0.50; Stop loss at $0.05 (signaling imminent delisting or further fundamental decay).
Portfolio Allocation
0.1% for aggressive risk tolerance (purely speculative, 'play money').
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is VSEE Financially Healthy?
Profitability
Gross Margin
46.13%
Operating Margin
-77.40%
Net Margin
-97.05%
Return on Equity
-177.53%
EPS
$-0.48
Balance Sheet
Current Ratio
0.52
Quick Ratio
0.50
Debt/Equity
0.60
Other
Beta (Volatility)
0.46
Does VSEE Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
VSEE lacks any discernible economic moat. Its competitive position is weak due to financial distress and a highly competitive telehealth market dominated by larger, better-funded players. Any existing user base or technology is insufficient to create a durable advantage.
Moat Erosion Risks
- •Larger, better-capitalized competitors (e.g., Teladoc, Amwell) can easily outspend and out-innovate VSEE.
- •Lack of funding to invest in R&D or marketing to build switching costs or brand recognition.
VSEE Competitive Moat Analysis
Sign up to see competitive advantages
VSEE Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Bearish (likely very low engagement, focused on delisting concerns if any discussion exists)
Institutional Sentiment
Negative (Delisting notice outweighs Armistice Capital's small stake; no analyst coverage indicates institutional disinterest)
Insider Activity (Form 4)
Armistice Capital and Steven Boyd reported a 9.99% ownership stake (4,861,392 shares) in a Schedule 13G/A filed on 2026-05-15. This suggests some institutional accumulation, though without Form 4 data, broader insider buying/selling is unknown.
Options Flow
Normal options activity (likely minimal volume given micro-cap status and low price)
Earnings Intelligence
Next Earnings
Q2 FY2026 (estimated mid-August 2026, based on typical reporting cycles after the 10-Q for Q1 FY2026 was filed May 15, 2026)
Surprise Probability
Low (without analyst estimates, any positive surprise would be highly unexpected given past performance)
Historical Earnings Pattern
Unknown (likely negative reactions to poor performance, but no data provided)
Key Metrics to Watch
Competitive Position
Top Competitor
Teladoc Health (TDOC)
Market Share Trend
Losing/Minimal (operating in a competitive telehealth market without evident growth or market leadership)
Valuation vs Peers
Highly speculative; VSEE is valued at distressed asset levels, making traditional peer comparison difficult. It trades at a deep discount, but this reflects its severe financial and regulatory risks.
Competitive Advantages
- •Potentially specialized niche in enterprise/government telehealth solutions (if applicable from training data, as not specified in research)
- •Established, albeit struggling, platform with existing customer base (from training data)
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive VSEE Stock Higher?
Near-Term (0-6 months)
- •Outcome of NASDAQ staff delisting notice appeal (estimated Q2/Q3 2026): A positive appeal outcome is critical for continued public trading, preventing value erosion from OTC migration.
- •Q1 FY2026 10-Q results (reported on 2026-05-15, but contents not provided): If revenue shows unexpected positive growth or cash burn significantly reduces from -$5.79M TTM, it could signal a very early, highly speculative turnaround.
Medium-Term (6-18 months)
- •Successful capital raise (est. Q4 2026 - Q2 2027): Securing significant new funding (e.g., $5M-$10M) to stabilize operations and provide working capital, assuming delisting is avoided.
- •Announcement of a strategic partnership with a major healthcare provider or tech firm (est. Q1 - Q3 2027): A partnership that could bring new revenue streams or validate VSee's technology and market presence, especially for its telehealth platform.
Long-Term (18+ months)
- •Significant adoption of new telehealth or remote patient monitoring solutions (If delisting is avoided and capital secured by FY2027, the company could achieve a ~$20M+ annual revenue run-rate by FY2029).
- •Successful pivot or acquisition of core technology by a larger entity (If operations stabilize and product gains traction by FY2028, VSEE could become an acquisition target for its IP/user base, potentially valuing the company at 1-2x revenue).
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for VSEE?
- ✓
Watch for the outcome of the NASDAQ delisting appeal, as a negative decision would be a severe blow to the investment thesis.
- ✓
Monitor any announcements of significant new capital infusions or major strategic partnerships that could provide a lifeline.
- ✓
Observe quarterly financial reports for any stabilization or improvement in operating cash flow or reduction in negative net income from Q1 FY2026 levels.
Bull Case Analysis
Sign up free to see the bull case
Competing with VSEE
See how Vsee Health Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Vsee Health Inc VSEE | $9.0M | 0.5 | — | — | -97.0% | — | |
AbbVie Inc ABBV | $381.1B | 0.1 | 104.8 | $15.0B | 5.8% | 9.5% | Compare → |
Johnson & Johnson JNJ | $557.1B | 1.0 | 26.5 | — | 21.8% | 7.9% | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $146.4B | 4.0 | 19.5 | $62.6B | 11.8% | 1.4% | Compare → |
UnitedHealth Group Inc UNH | $365.5B | 0.3 | 30.3 | $447.6B | 2.7% | 9.7% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Vsee Health Inc Makes Money
Vsee Health Inc is a healthcare technology company that historically focused on providing secure, HIPAA-compliant telehealth and telemedicine solutions. Their platform typically enables virtual consultations, remote patient monitoring, and secure health data exchange for healthcare providers, enterprises, and potentially government agencies. The company aims to monetize its technology through software licenses, subscription fees, or service contracts for its telehealth platform, though current financial performance suggests severe challenges in achieving profitability or scaling these revenue streams.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Vsee Health Inc (VSEE)?
As of May 31, 2026, Vsee Health Inc has a DVR Score of 0.5 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Vsee Health Inc?
Vsee Health Inc's market capitalization is approximately $9.0M. The company operates in the Healthcare sector within the Health Information Services industry.
What ticker symbol does Vsee Health Inc use?
VSEE is the ticker symbol for Vsee Health Inc. The company trades on the NCM.
What is the risk level for VSEE stock?
Our analysis rates Vsee Health Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
Is VSEE stock profitable?
Vsee Health Inc has a profit margin of -97.0%. The company is currently unprofitable.
How often is the VSEE DVR analysis updated?
Our AI-powered analysis of Vsee Health Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 31, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for VSEE (Vsee Health Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.